Please note that this service handles press enquiries from journalists only.
If you require information or advice about your medication or treatment please contact your healthcare professional.
More information about our products can be found by following the links to the appropriate business area.
Media Releases
Press releases listed on this page were issued in the United Kingdom and are intended for reference information. The information contained in each press release was accurate at the time of issuance, and Novartis Pharmaceuticals UK Limited assumes no responsibility for updating the information to reflect subsequent developments.
Novartis UK will continue to supply pharmaceuticals into community via wholesale using simplified distribution network.
New licence for Cubicin® (daptomycin), the first in a novel class of antibiotic, is announced today for the treatment of serious bloodstream and heart infections caused by the most problematic UK organisms, including MRSA
Clinicians welcome NICE decision to grant NHS patients access to Xolair® (omalizumab) - a first-in-class treatment for severe, persistent allergic asthma
Novartis treatment for patients with severe, persistent allergic asthma has been awarded a prestigious Prix Galien award for innovative research and development.